Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Bionomy Health vs JRNYS

Bionomy Health
Graded #182

Higher grade

vs+4.099999999999994
JRNYS
Graded #267

Lower grade

The verdict

Bionomy Health takes it — 66.6/100 to 62.5/100.

Bionomy Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Bionomy Health is a physician-led, direct-to-consumer men's telehealth service selling compounded GLP-1 weight-loss medication alongside testosterone, peptides and longevity protocols.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBionomy Health +2
47
45
Dose & formulationBionomy Health +17
75
58
Clinical oversightJRNYS +6
78
84
Labs & monitoringJRNYS +9
62
71
FulfillmentBionomy Health +24
89
65
Contract termsJRNYS +2
53
55
Bionomy Health · left barJRNYS · right bar

The numbers

MetricBionomy HealthJRNYS
WeighScore66.6/10062.5/100
GradeCC
Scorecard rank#182#267
Semaglutide$189/mo (starting dose, compounded)Not disclosed
Tirzepatide$249/mo (compounded)Not disclosed
Coverage48 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Bionomy Health

Graded #182 · C

Strengths

  • Cancellation is genuinely unconditional: no subscription, no card on file, no auto-renewal, no cancellation fee — you pay per refill
  • Prices are published before intake on a dedicated GLP-1 page, and the same figures appear in the site's own llms.txt
  • Available in 48 states

Where it loses points

  • The $189 is a starting rate, not a flat one: the page says 'From', the product card says 'Starter', and doses are titrated every four weeks with no published price for the dose you end up on
  • The homepage says muscle preservation is 'included' while the GLP-1 page sells a Muscle Preserve Pack at $109/mo as a separate line item
  • No FDA-approved pathway and no oral route — the site does not mention Wegovy, Ozempic, Zepbound or Mounjaro at all
  • Not available in Alaska or Hawaii
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
JRNYS

Graded #267 · C

Strengths

  • Branded, FDA-approved GLP-1s — Wegovy, Ozempic, Zepbound, Mounjaro and Saxenda — rather than compounded copies
  • The membership band is published before intake and is banded openly by level of coach support
  • Medical visits, daily monitoring and 1-on-1 coaching are included in the membership at every tier
  • Led by CMO Dr. Henry Legere (UC Berkeley, Columbia medicine, Harvard fellowship)
  • Members with commercial insurance may pay around $25 a month for the medication after any deductible

Where it loses points

  • The membership is overhead, not a medication price: it covers visits, monitoring and coaching, and the FAQ says medication pricing is confirmed only after a provider consultation
  • No self-pay drug price is published anywhere, so the cost of a month cannot be worked out before signing up
  • The best case depends on commercial insurance coverage; without it the medication cost is unknown
  • No compounded option is disclosed — the programme is brand-focused, and brand list prices are the dearest route to a GLP-1
  • The states it can prescribe in are not published

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard